TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1314711
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of trivalent oral poliovirus vaccine (TOPV) at 2, 4, and 6 months of age (Group B)
Study: 25900227
Drug: Remifentanil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.1 μg/kg/min infusion
Study: 25900227
Drug: Remifentanil 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.3 μg/kg/min infusion
Study: 21124330
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 mg/day increased to 10 mg/day)
Study: 20008241
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclophosphamide, thalidomide, and dexamethasone
Study: 20008241
Drug: Standard MPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard MPT or MPV with reduced doses
Study: 20008241
Drug: Accurate management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accurate management of treatment-related adverse events
Study: 17996133
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy for coronary heart disease (Control)
Study: 15485433
Drug: Open irrigated‐tip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open irrigated‐tip catheter (group B, 65 degrees C, 50 W, 60 s, 17 mL/min flow)
Study: 9704873
Drug: moclobemide (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: moclobemide (450 mg/day)
Study: 9704873
Drug: clomipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: clomipramine (150 mg/day)
Study: 82680
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g/day) for 3, 6, 9, or 12 months
Study: 82680
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g/day) for 1 year
Study: 27922948
Drug: 24-hour morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour morphine use
Study: 23233710
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy plus iodine-131 tositumomab (CHOP-RIT)
Study: 20141067
Drug: Local diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local diltiazem ointment (group D)
Study: 20141067
Drug: Local glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local glyceryl trinitrate ointment (group GTN)
Study: 20141067
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of botulinum toxin (group BT)
Study: 12945826
Drug: Analysis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analysis of nutrients (e.g., vitamin C, vitamin A, cholesterol)
Study: 10532600
Drug: RBC transfusions
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC transfusions if Hb < 8 g/dL or predetermined clinical conditions
Study: 10532600
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated according to physician's orders (Hb < 9 g/dL)
Study: 7080769
Drug: Inactivated chromatographic
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated chromatographic influenza vaccine A(H3N2)
Study: 24767719
Drug: 6-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-day course of daily prednisolone therapy during an upper respiratory tract infection (URTI)
Study: 24767719
Drug: No change
Approvals — FDA: no, EMA: no, PMDA: no
Description: No change to current therapy (placebo)
Study: 15783019
Drug: Dai-kenchu-to (DKT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dai-kenchu-to (DKT) 5g administered orally three times a day
Study: 15783019
Drug: Lactulose 16g
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose 16g administered orally three times a day
Study: 10532092
Drug: Aminoglutethimide (AG)
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide (AG) 250 mg twice daily with corticosteroid support
Study: 8530996
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation not modified and local tranexamic acid applied during and after surgery
Study: 8530996
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation reduced and calcium heparin added preoperatively
Study: 7113711
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg (D)
Study: 7113711
Drug: Alcohol 0.5
Normalized name: isopropyl alcohol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.5 g/kg (A)
Study: 7113711
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg (D) + Alcohol 0.5 g/kg (A)
Study: 27903924
Drug: Cabazitaxel (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (20 mg/m2, increased to 25 mg/m2 for subsequent cycles if tolerated)
Study: 16205597
Drug: Dose dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose dense chemotherapy incorporating AC and paclitaxel
Study: 8901799
Drug: Sour milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sour milk (Calpis), 95 mL daily for 8 weeks
Study: 8901799
Drug: Placebo (artificially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (artificially acidified milk), 95 mL daily for 8 weeks
Study: 6848468
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n = 50)
Study: 26541103
Drug: Central air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central air injection
Study: 26541103
Drug: Peripheral air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral air injection
Study: 23453547
Drug: Early enteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early enteral fat supplement and fish oil
Study: 17698733
Drug: cTnT assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: cTnT assay (detection limit < or = 0.01 ng/mL)
Study: 17698733
Drug: hsTnT assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsTnT assay (detection limit < or = 0.001 ng/mL)
Study: 12192353
Drug: Ibuprofen syrup
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen syrup (10 mg/kg 3 times a day for 5 days)
Study: 10665199
Drug: Intra‐oral fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra‐oral fluoride releasing device (IFRD) releasing 0.04 mg/day of fluoride for 12 months
Study: 2566250
Drug: Midazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.25 mg kg‐1)
Study: 2566250
Drug: Thiopentone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (5 mg kg‐1)
Study: 998556
Drug: Raw wheat
Normalized name: Potassium/Wheat Germ 250 MG Oral Powder [NATURFRESH RAW WHEAT GERM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw wheat bran 12 g/day
Study: 998556
Drug: Raw wheat
Normalized name: Potassium/Wheat Germ 250 MG Oral Powder [NATURFRESH RAW WHEAT GERM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw wheat bran 20 g/day
Study: 998556
Drug: Cooked bran
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooked bran 13.2 g/day
Study: 998556
Drug: Cooked bran
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooked bran 22 g/day
Study: 31601496
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg/kg intravenous, administered 1-42 days after chemoradiotherapy, then every 2 weeks up to 12 months)
Study: 31601496
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo administered 1-42 days after chemoradiotherapy, then every 2 weeks up to 12 months)
Study: 17203750
Drug: HAI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI plus systemic chemotherapy (HAI+SYC)
Study: 14622075
Drug: Cognitive‐behavioral analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral analysis system of psychotherapy (CBASP) with medication
Study: 8958493
Drug: Ketamine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 3 mg kg‐1
Study: 8958493
Drug: Ketamine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 6 mg kg‐1
Study: 8958493
Drug: Placebo (cola
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cola 0.2 mL kg‐1)
Study: 3293643
Drug: diamorphine in
Normalized name: Product containing diamorphine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: diamorphine in 0.9% saline (0.5 mg in 15 ml)
Study: 3293643
Drug: diamorphine mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: diamorphine mixed with 0.125% bupivacaine (0.5 mg in 15 ml)
Study: 29348380
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa seed extract 300 mg twice daily for 28 days
Study: 21849027
Drug: Brief Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Intervention (BI) combined with treatment as usual
Study: 19022547
Drug: Standard multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multivitamin containing high doses of folic acid and vitamins B(6) and B(12)
Study: 17252186
Drug: Two cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of 'eight-drugs-in-one-day' (8-in-1) chemotherapy followed by involved-field radiotherapy and six cycles of 8-in-1 chemotherapy
Study: 12808771
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution
Study: 1732770
Drug: Nonionic, low-osmolality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonionic, low-osmolality radiocontrast agents
Study: 1732770
Drug: Ionic, high-osmolality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic, high-osmolality radiocontrast agents
Study: 31436835
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg once daily (QD)
Study: 26915483
Drug: CUR 320
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CUR 320 mg/day
Study: 17289537
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa administered once monthly
Study: 9663889
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin ointment applied at the catheter exit site (daily or three times per week)
Study: 9663889
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin ointment applied at the catheter exit site
Study: 2495214
Drug: Lactose-free pelletized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-free pelletized sodium cromoglycate (20 mg)
Study: 2495214
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate plus lactose (20 mg)
Study: 841307
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cocaine hydrochloride intranasally
Study: 841307
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg cocaine hydrochloride intranasally
Study: 841307
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg cocaine hydrochloride intranasally
Study: 841307
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cocaine hydrochloride intravenously
Study: 841307
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg cocaine hydrochloride intravenously
Study: 29937865
Drug: ART/TB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART/TB treatment arm
Study: 29937865
Drug: TB alone
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB alone treatment arm
Study: 23690688
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment alone
Study: 23690688
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antihypertensive treatment with effective CPAP
Study: 23690688
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment with effective CPAP
Study: 21950232
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 2% Lidocaine Hydrochloride into the fracture hematoma (Group B)
Study: 19801055
Drug: Time Pressure
Normalized name: Sudafed PE Sinus Daytime Pressure + Pain + Cough Solution (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time Pressure Management (TPM) strategy, 10 hours of treatment
Study: 3316296
Drug: Chlorhexidine acetate
Normalized name: Chlorhexidine Acetate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine acetate chewing gum (5 mg per piece)
Study: 3316296
Drug: Chlorhexidine acetate
Normalized name: Chlorhexidine Acetate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine acetate chewing gum with hydrogen peroxide releasing agent
Study: 3316296
Drug: Control gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control gum (gum base with flavoring agents, no CHX or H2O2)
Study: 26044391
Drug: Lysine-derived urethane
Normalized name: Urethane
DrugBank: Urethane (DB04827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine-derived urethane adhesive (Treatment group)
Study: 15984585
Drug: Conventional mono
Normalized name: tiotropium bromide mono
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional mono mac therapy (20 mg twice a day)
Study: 15984585
Drug: Mono mac
Normalized name: tiotropium bromide mono
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mono mac chronotherapy (10 to 20 mg 30 minutes before PMI episodes)
Study: 12610046
Drug: GLP-1 at
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 at a dose of 1.5 pmol.kg(‐1)x min(‐1)
Study: 10496529
Drug: MSI-L gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSI-L gastric adenomas
Study: 10496529
Drug: MSI-L gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSI-L gastric carcinomas
Study: 10496529
Drug: MSI-L tumors
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSI-L tumors
Study: 8621746
Drug: Fenfluramine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (60 mg oral dose)
Study: 1769410
Drug: Papaverine hydrochloride
Normalized name: Papaverine Hydrochloride
DrugBank: Papaverine (DB01113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Papaverine hydrochloride (150-300 mg t.i.d.)
Study: 7107102
Drug: Fixed Anaerobic
Normalized name: Peptostreptococcus anaerobius
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Anaerobic Threshold of 4 mmol.l(-1) lactate (ATc)
Study: 31682026
Drug: 1-L PEG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-L PEG, 4 h before VCE
Study: 31682026
Drug: 1-L PEG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-L PEG, 12 h before VCE
Study: 31682026
Drug: 2-L PEG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L PEG, 12 h before VCE
Study: 31682026
Drug: 2-L PEG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L PEG, 4 h before VCE
Study: 28035924
Drug: Donepezil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (10 mg/day) plus Choline Alphoscerate (1200 mg/day)
Study: 28035924
Drug: Donepezil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (10 mg/day) plus Placebo
Study: 26310362
Drug: Active Treatment
Normalized name: Active
DrugBank: Octisalate (DB11062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Treatment Condition (ATC)
Study: 19514089
Drug: EGF 50
Normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: EGF 50 microg/mL
Study: 17543813
Drug: 0.25% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% levobupivacaine as a bolus and/or 50‐hour infusion
Study: 8573702
Drug: Feedback of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback of eye movements treatment (wearing glasses providing a reminder bleep if patients failed to move their eyes to the left in a 15 s interval) for 2 h 40 min a week for 4 weeks.
Study: 8573702
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for visual inattention).
Study: 2677240
Drug: Brofaromine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine (25 mg bid, 50 mg bid, 75 mg bid)
Study: 2677240
Drug: Tranylcypromine 20
Normalized name: tranylcypromine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranylcypromine 20 mg/day
Study: 2677240
Drug: Nomifensine 100
Normalized name: nomifensine
DrugBank: Nomifensine (DB04821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nomifensine 100 mg/day
Study: 25050869
Drug: Amlodipin (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipin (5-10 mg/d)
Study: 25050869
Drug: Verapamil (120-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120-240 mg/d)
Study: 23556460
Drug: Fiber supplements
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber supplements (GA, PSY, CMC)
Study: 21931737
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) rAd5 vaccine boost
Study: 21931737
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) rAd5 vaccine boost
Study: 21931737
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) rAd5 vaccine boost
Study: 21931737
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving rAd5 vaccine boost)
Study: 17240799
Drug: Chemoradiotherapy (radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (radiotherapy plus injection cisplatin 30 mg/m2 once weekly for 5 weeks)
Study: 12788885
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg DHEA after 4 days of dexamethasone (Dex; 4 x 0.5 mg/d)
Study: 12788885
Drug: Dexamethasone (Dex;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (Dex; 4 x 0.5 mg/d)
Study: 12788885
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after 4 days of dexamethasone (Dex; 4 x 0.5 mg/d)
Study: 8972377
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (0.5 ml of balanced salt solution) for conjunctival wound closure (Group B)
Study: 8972377
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (Group B)
Study: 1358607
Drug: Ondansetron 16
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 16 mg three times daily
Study: 4089582
Drug: timolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol (10 mg/d, n = 14)
Study: 4089582
Drug: methyldopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: methyldopa (250 mg/d, n = 16)
Study: 4089582
Drug: hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide (25 mg/d) and amiloride (2.5 mg/d)
Study: 22683613
Drug: Plerixafor plus
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor plus granulocyte colony-stimulating factor (G-CSF)
Study: 22683613
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus granulocyte colony-stimulating factor (G-CSF)
Study: 16124423
Drug: Rectal artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rectal artesunate (initial dose of 40 mg/kg bodyweight, in 3 or 4 divided doses in the first 24 hours, followed by 10 mg/kg bodyweight once daily for three consecutive days)
Study: 16124423
Drug: Rectal artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rectal artesunate (high initial dose regimen of 20 mg/kg bodyweight)
Study: 8334064
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of atenolol 50 mg and nifedipine retard 20 mg (Tenif) once daily
Study: 29775957
Drug: MAS‐XR (60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAS‐XR (60mg or 80mg daily)
Study: 27132212
Drug: MAGE‐A3 immunotherapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE‐A3 immunotherapeutic (no chemotherapy)
Study: 27132212
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no chemotherapy)
Study: 11778184
Drug: Levofloxacin (LVLX)
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin (LVLX) at a dose of 300 mg/d
Study: 11778184
Drug: Ofloxacin (OFLX)
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin (OFLX) at a dose of 600 mg/d
Study: 6695025
Drug: Silicone-gel prostheses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone-gel prostheses
Study: 22028294
Drug: Personalized therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized therapy based on ERCC1 and RRM1 expression
Study: 22028294
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Trial A, B, C)
Study: 18074942
Drug: Myo-inositol plus
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myo-inositol plus folic acid (4 g myo-inositol plus 400 mcg folic acid)
Study: 18074942
Drug: Placebo (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (400 mcg folic acid)
Study: 2296878
Drug: Diltiazem, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem, 60 mg three times daily